Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy

  • Technology appraisal guidance
  • TA428
  • Published: 
  • Last updated: 
Download guidance (PDF)

1 Recommendations

1.1 Pembrolizumab is recommended as an option for treating locally advanced or metastatic PD‑L1‑positive non‑small‑cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]‑positive tumour), only if:

  • pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression, and

  • the company provides pembrolizumab in line with the commercial access agreement with NHS England.

1.2 This guidance is not intended to affect the position of patients whose treatment with pembrolizumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.